FABP Biotech is a spin-off of the Oswaldo Cruz Foundation created under the regulatory framework of the Brazilian Technological Innovation Law to develop anti-helminth vaccines for animal use.
FABP Biotech holds the exclusive licensing of patents and rights for the final development, registration, and commercialization of vaccines and veterinary products based on Sm14.
The Sm14 Fatty Acid Binding Protein elicits a robust immune response in animals with helminth infections, making it a promising target for a multivalent vaccine. A range of globally filed and granted patents describe the use of Sm14 in vaccines, and researchers continue to explore its potential as a prophylactic and therapeutic tool.
FABP Biotech currently explores the Sm14 technology in two ways:
1. LIVAC ® — Sm14 vaccine to prevent fasciolosis in livestock (cattle, goats, and sheep).
2. Sm14PET — Sm14 vaccine for worms that affect pets, such as heartworm.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Rua Lasar Segall, Rio De Janeiro,rj,brazil
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.fabpbiotech.com.br
- Keywords
- vaccines, veterinary parasites, fasciolosis, heartworm, Fasciola hepatica, Dirofilaria immitis.
- HQ
- Rio de Janeiro, RJ
Fabp Biotech Questions
Fabp Biotech's website is https://www.fabpbiotech.com.br
Fabp Biotech's LinkedIn profile is https://br.linkedin.com/company/fabp-biotech
Fabp Biotech has
11 employees.
View email and phone details for 11
employees at Fabp Biotech.
Fabp Biotech's industry is
Biotechnology Research
Fabp Biotech's top competitors are
Onecup Ai,
Astra Therapeutics,
Omnium Global,
Allegro Biotech,
Benno Therapeutics,
Stmpatch - Singletimemicroneedles,
Organicin Scientific,
Resilient Biotics,
Verovaccines Gmbh,
Peptidus Biotech.
Fabp Biotech's categories are Biotechnology Research
Fabp Biotech's founding year is 2020
